<DOC>
	<DOC>NCT00662818</DOC>
	<brief_summary>The purpose of this study is to evaluate the safety and efficacy of telcagepant in the treatment of acute migraine in participants with stable vascular disease. Acetaminophen/paracetamol (APAP) will be used as an active comparator in this study. The primary hypothesis of this study is that telcagepant 300 mg is superior to placebo.</brief_summary>
	<brief_title>Telcagepant (MK-0974) Treatment of Migraine in Participants With Stable Vascular Disease (MK-0974-034)</brief_title>
	<detailed_description />
	<mesh_term>Heart Diseases</mesh_term>
	<mesh_term>Migraine Disorders</mesh_term>
	<mesh_term>Vascular Diseases</mesh_term>
	<mesh_term>Stroke</mesh_term>
	<mesh_term>Peripheral Vascular Diseases</mesh_term>
	<mesh_term>Peripheral Arterial Disease</mesh_term>
	<mesh_term>Ischemic Attack, Transient</mesh_term>
	<mesh_term>Acetaminophen</mesh_term>
	<criteria>Stable coronary artery disease for 3 months or more 18 years of age or older with a history of migraine with or without aura Must use acceptable contraception throughout the study Pregnant, breastfeeding, or planning to become pregnant during this study 50 years of age or older when migraines began Other pain syndromes that might interfere with study assessments, uncontrolled psychiatric conditions, dementia, or significant neurological disorders (other than migraine) History of gastric, or small intestinal surgery, or has a disease that causes malabsorption</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2015</verification_date>
</DOC>